Compare PASG & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASG | ASBP |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 12.3M |
| IPO Year | 2020 | 2021 |
| Metric | PASG | ASBP |
|---|---|---|
| Price | $3.48 | $7.30 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | 13.1K | ★ 27.0K |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $3.31 |
| 52 Week High | $20.00 | $367.50 |
| Indicator | PASG | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 40.25 |
| Support Level | $3.29 | $7.19 |
| Resistance Level | $5.03 | $8.11 |
| Average True Range (ATR) | 0.25 | 0.57 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 3.17 | 13.59 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Aspire-Lakewood Holdings Inc is a United States-based company. Along with its subsidiary, it is involved in the design and manufacture of engineered automotive and industrial control systems that combine mechanical engineering, electronics, and computer science to provide intelligent, automated systems for vehicle electrification, safety, lightweighting, and sustainability. DCSC maintains a powertrain-agnostic product portfolio that includes mechatronic actuators, human-machine interfaces, industrial cables, and cable control systems backed by over 310 patents. The Company operates around 11 manufacturing facilities globally and serves as a tier-one automotive supplier to OEMs and other industrial firms.